[Prevention of type 2 diabetes mellitus due to antihypertensive treatment affecting renin-angiotensin system].

Prevence vzniku diabetu 2. typu pri lécbe antihypertenzivy ovlivnujícími systém renin-angiotenzin.

Publisher: Ambit Media Country of Publication: Czech Republic NLM ID: 0413602 Publication Model: Print Cited Medium: Print ISSN: 0042-773X (Print) Linking ISSN: 0042773X NLM ISO Abbreviation: Vnitr Lek Subsets: MEDLINE

Publication: 2010- : Brno : Ambit Media
Original Publication: 1973-<1994> : Praha : Avicenum

Angiotensin II Type 1 Receptor Blockers/*therapeutic use ; Angiotensin-Converting Enzyme Inhibitors/*therapeutic use ; Antihypertensive Agents/*therapeutic use ; Diabetes Mellitus, Type 2/*prevention & control ; Hypertension/*drug therapy ; Renin-Angiotensin System/*drug effects; Angiotensin II Type 1 Receptor Blockers/pharmacology ; Angiotensin-Converting Enzyme Inhibitors/pharmacology ; Animals ; Antihypertensive Agents/pharmacology ; Diabetes Mellitus, Type 2/metabolism ; Humans ; Hypertension/metabolism ; Insulin Resistance

Hypertension is often associated with an impairment of glucose tolerance and is a risk factor for the development of type 2 diabetes mellitus. The occurrence of diabetes may be also influenced by the selection of the type of antihypertensive treatment. While it has been shown that the use of older type antihypertensives - diuretics and beta-blockers - may precipitate diabetes, newer drugs which inhibit the renin-angiotensin system have a positive effect on glucose tolerance. Several recent clinical trials of ACE-inhibitors and AT1-blockers have demonstrated a decreased risk of the occurrence of diabetes in comparison with placebo or conventional antihypertensive drugs. The mechanisms responsible for the antidiabetic effect of these newer antihypertensive agents remain largely speculative. Insulin resistance may be improved in several ways, e.g. by changes in microcirculation or direct effects on insulin response and glucose transport in target organ cells. However, as shown in experimental studies, improved islet function and insulin secretion may also have role due to an inhibitory effect on the local renin-angiotensin system in the pancreas. Ongoing prospective clinical trials having the occurrence of diabetes as a primary specified endpoint should confirm the preventive potential of the inhibitors of the renin-angiotensin system. Since direct comparisons are lacking, current data are inconclusive as to the superiority of one of the two classes of these inhibitors or of any single drug. Nevertheless, inhibitors of the renin-angiotensin system should definitely represent first choice antihypertensive agents for persons with additional risk factors such as family history of diabetes, obesity or impaired glucose tolerance.

34

0 (Angiotensin II Type 1 Receptor Blockers)
0 (Angiotensin-Converting Enzyme Inhibitors)
0 (Antihypertensive Agents)

Date Created: 20061110 Date Completed: 20070111 Latest Revision: 20061109

20221213

17091602